placeholder
MAJOR78
CLINICAL TRIALLimited grounding
Retatrutide hit 28.7% weight loss; PatentVest says the next fight is IP - Stock Titan
Retatrutide, a new weight-loss drug, showed patients lost 28.7% of their body weight in testing. PatentVest says the company's next big challenge will be protecting its patents so competitors can't copy the drug.
Analysis
Retatrutide's 28.7% weight loss sets a new efficacy bar for Lilly's obesity franchise, but the durability of the lead now hinges on IP defense against fast-following competitors.
- Retatrutide produced 28.7% body weight loss in testing
- PatentVest flags IP protection as the next competitive battleground
Retatrutide News4d
Read